Transactions
30
Insider / INSMED Inc
Smith Michael Alexander
Chief Legal Officer at INSMED Inc
- Company
- INSMED Inc
- Ticker
- INSM
- First filing on record
- November 5, 2025
- Latest trade on record
- June 22, 2026
- SEC filings
- EDGAR ↗
Smith Michael Alexander, Chief Legal Officer at INSMED Inc, has disclosed 30 transactions in INSM since November 5, 2025: 0 purchases (0 open-market buys) and 20 sales, worth about $15.5M at the reported prices. The latest was filed June 24, 2026, 2 days after the trade.
Open-market buys
0
Sales
20
Avg. disclosure lag
1.6d
Trading in charts
Trade timeline
When does this person trade, how big, and in which direction? Every trade in the last 12 months.
Bought (above the line)Sold (below the line)Other transaction
In the last 12 months Smith Michael Alexander made no purchases and 20 sales worth $14M, plus 10 other transactions. Dot size is the dollar amount.
Portfolio mix
Which stocks does this person trade most? Tile size is dollars traded, all time on record.
Smith Michael Alexander has traded 1 stock on record; the largest by dollars is INSM.
Reporting lag
Does this person report on time? One bar per filing against the Form 4 deadline.
On timeLate
0 of 10 filings on record were reported after the Form 4 deadline (two business days, counted here as 4 calendar days).
What kind of transactions
Most Form 4 rows are pay arriving or tax being withheld, not a decision to buy or sell. Only code P is an open-market purchase and code S an open-market sale. What each code means: Form 4 transaction codes.
| Code | Meaning | Rows | Shares | Value |
|---|---|---|---|---|
| S | Open-market sale | 20 | 89,563 | $14.0M |
| M | Option exercise or conversion | 8 | 134,032 | $1.5M |
| A | Grant or award | 2 | 32,893 | — |
| Year | Rows | Bought | Sold |
|---|---|---|---|
| 2026 | 20 | 0 | 12 · $9.0M |
| 2025 | 10 | 0 | 8 · $5.0M |
Transactions
| Security | Side | Trade date | Disclosed | Lag | Shares | Price | Value | Flags | Source | Share |
|---|---|---|---|---|---|---|---|---|---|---|
| INSM | Sell S | June 22, 2026 | June 24, 2026 | 2d | 1,806 | $96 | $173K | 10b5-1 plan | Form 4 ↗ | |
| INSM | Sell S | June 3, 2026 | June 5, 2026 | 2d | 2,159 | $102 | $221K | Form 4 ↗ | ||
| INSM | Sell S | May 22, 2026 | May 22, 2026 | 0d | 6,149 | $108 | $667K | 10b5-1 plan | Form 4 ↗ | |
| INSM | Sell S | May 13, 2026 | May 15, 2026 | 2d | 4,109 | $116 | $477K | Form 4 ↗ | ||
| INSM | Option / conversion M | March 30, 2026 | March 31, 2026 | 1d | 13,989 | — | — | 10b5-1 planderivative | Form 4 ↗ | |
| INSM | Option / conversion M | March 30, 2026 | March 31, 2026 | 1d | 5,649 | — | — | 10b5-1 planderivative | Form 4 ↗ | |
| INSM | Sell S | March 30, 2026 | March 31, 2026 | 1d | 19,638 | $151 | $3.0M | 10b5-1 plan | Form 4 ↗ | |
| INSM | Option / conversion M | March 30, 2026 | March 31, 2026 | 1d | 13,989 | $28 | $390K | 10b5-1 plan | Form 4 ↗ | |
| INSM | Option / conversion M | March 30, 2026 | March 31, 2026 | 1d | 5,649 | $17 | $96K | 10b5-1 plan | Form 4 ↗ | |
| INSM | Option / conversion M | February 24, 2026 | February 25, 2026 | 1d | 20,248 | — | — | 10b5-1 planderivative | Form 4 ↗ | |
| INSM | Sell S | February 24, 2026 | February 25, 2026 | 1d | 15,771 | $157 | $2.5M | 10b5-1 plan | Form 4 ↗ | |
| INSM | Sell S | February 24, 2026 | February 25, 2026 | 1d | 4,151 | $155 | $644K | 10b5-1 plan | Form 4 ↗ | |
| INSM | Sell S | February 24, 2026 | February 25, 2026 | 1d | 4,852 | $154 | $747K | 10b5-1 plan | Form 4 ↗ | |
| INSM | Option / conversion M | February 24, 2026 | February 25, 2026 | 1d | 20,248 | $17 | $346K | 10b5-1 plan | Form 4 ↗ | |
| INSM | Sell S | February 3, 2026 | February 4, 2026 | 1d | 640 | $156 | $100K | Form 4 ↗ | ||
| INSM | Sell S | January 8, 2026 | January 8, 2026 | 0d | 1,053 | $174 | $183K | Form 4 ↗ | ||
| INSM | Sell S | January 7, 2026 | January 8, 2026 | 1d | 709 | $175 | $124K | Form 4 ↗ | ||
| INSM | Sell S | January 6, 2026 | January 8, 2026 | 2d | 1,396 | $173 | $242K | Form 4 ↗ | ||
| INSM | Other A | January 2, 2026 | January 6, 2026 | 4d | 27,600 | — | — | derivative | Form 4 ↗ | |
| INSM | Other A | January 2, 2026 | January 6, 2026 | 4d | 5,293 | — | — | Form 4 ↗ | ||
| INSM | Option / conversion M | November 3, 2025 | November 5, 2025 | 2d | 27,130 | — | — | 10b5-1 planderivative | Form 4 ↗ | |
| INSM | Sell S | November 3, 2025 | November 5, 2025 | 2d | 1,400 | $188 | $263K | 10b5-1 plan | Form 4 ↗ | |
| INSM | Sell S | November 3, 2025 | November 5, 2025 | 2d | 1,572 | $187 | $294K | 10b5-1 plan | Form 4 ↗ | |
| INSM | Sell S | November 3, 2025 | November 5, 2025 | 2d | 3,636 | $186 | $676K | 10b5-1 plan | Form 4 ↗ | |
| INSM | Sell S | November 3, 2025 | November 5, 2025 | 2d | 3,243 | $185 | $600K | 10b5-1 plan | Form 4 ↗ | |
| INSM | Sell S | November 3, 2025 | November 5, 2025 | 2d | 4,032 | $184 | $742K | 10b5-1 plan | Form 4 ↗ | |
| INSM | Sell S | November 3, 2025 | November 5, 2025 | 2d | 4,286 | $183 | $783K | 10b5-1 plan | Form 4 ↗ | |
| INSM | Sell S | November 3, 2025 | November 5, 2025 | 2d | 7,619 | $182 | $1.4M | 10b5-1 plan | Form 4 ↗ | |
| INSM | Sell S | November 3, 2025 | November 5, 2025 | 2d | 1,342 | $181 | $243K | 10b5-1 plan | Form 4 ↗ | |
| INSM | Option / conversion M | November 3, 2025 | November 5, 2025 | 2d | 27,130 | $24 | $644K | 10b5-1 plan | Form 4 ↗ |
Filings
| Filed | Form | Accession | Rows | Status | Source |
|---|---|---|---|---|---|
| June 24, 2026 | Form 4 | 0001870278-26-000020 | 1 | published | EDGAR ↗ |
| June 5, 2026 | Form 4 | 0001870278-26-000017 | 1 | published | EDGAR ↗ |
| May 22, 2026 | Form 4 | 0001870278-26-000015 | 1 | published | EDGAR ↗ |
| May 15, 2026 | Form 4 | 0001870278-26-000012 | 1 | published | EDGAR ↗ |
| March 31, 2026 | Form 4 | 0001870278-26-000010 | 5 | published | EDGAR ↗ |
| February 25, 2026 | Form 4 | 0001870278-26-000008 | 5 | published | EDGAR ↗ |
| February 4, 2026 | Form 4 | 0001870278-26-000006 | 1 | published | EDGAR ↗ |
| January 8, 2026 | Form 4 | 0001870278-26-000004 | 3 | published | EDGAR ↗ |
| January 6, 2026 | Form 4 | 0001870278-26-000002 | 2 | published | EDGAR ↗ |
| November 5, 2025 | Form 4 | 0001870278-25-000011 | 10 | published | EDGAR ↗ |
Other insiders at INSMED Inc
- Lewis William Chair and CEO 136 rows
- Flammer Martina M.D. Chief Medical Officer 67 rows
- Adsett Roger Chief Operating Officer 20 rows
- Schaeffer Orlov S Nicole Chief People Strategy Officer 15 rows
- Bonstein Sara Chief Financial Officer 10 rows
- SHAROKY MELVIN MD Director 9 rows
- LEE LEO Director 6 rows
- Brennan David R Director 5 rows
- ANDERSON ELIZABETH M Director 3 rows
- Butera Samuele SVP, GM, Global Respiratory 2 rows
Everyone on file, with contracts and lobbying under the company's name: INSMED Inc.
Guides for this page
- What is SEC Form 4? Who files: officers, directors and owners of more than 10% of a class of the company's shares.
- Form 4 transaction codes P = purchase. S = sale. These are the two market trades.
- Insider buying vs insider selling Selling outweighs buying by a wide margin in normal times.
- Rule 10b5-1 trading plans The plan must be set up when the insider has no important non-public information.
- Options and derivatives on Form 4 Table I = shares. Table II = options and other derivatives.
Sources and method
| Source | Filings | Rows | First filed | Newest filed | Read the originals |
|---|---|---|---|---|---|
| SEC EDGAR, Form 4 | 10 | 30 | November 5, 2025 | June 24, 2026 | Form 4 list on EDGAR |
Site built October 27, 2026. Every row in the tables above links to its own filing. To quote a figure, use the Cite button at the top of the page; see how to cite and reuse.
Every row comes from the reporting owner's Form 4 as filed with the SEC (EDGAR ownership XML), read daily. "Value" is shares × the reported price; code P is an open-market purchase, S a sale, M an option exercise, A a grant. The lag is the filing date minus the trade date; Form 4 is due within two business days. Amendments (4/A) are not merged. Details on the methodology page; report an error on corrections.
Not investment advice. Figures are public disclosures shown as filed; they may lag the trade and may be amended later. No recommendation is made or implied.